Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845400 · ClinicalTrials.gov registry record
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
A clinical trial, sponsored by Shire.
- Completed
- Registry status
- 168
- Enrollment target
NCT03845400: Completed study, sponsored by Shire.
NCT03845400 is a clinical trial that has completed, run by Shire. The registered enrollment target is 168 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03845400 has completed, sponsored by Shire.
- COMPLETED
- Registry status
- 168 participants
- Enrollment target
Study Summary
The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II. Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at study start and then every 3 months until the study ends; data will also be collected by the study doctor during routine clinic visits.
Primary Outcome
Number of HAE attacks before and after lanadelumab initiation will be reported.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2019-03-30 |
| Est. Completion | 2022-10-22 |
What the finished NCT03845400 record still lists
NCT03845400 is an observational study that tracks outcomes without assigning an intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03845400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03845400 about?
NCT03845400 is a clinical study titled "A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America". The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II. Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at st...
What is the current status of trial NCT03845400?
This trial is currently completed. The enrollment target is 168 participants. The study started on 2019-03-30. Estimated completion is 2022-10-22.
Who is sponsoring clinical trial NCT03845400?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI